Skip to main content

Vietnam to Punish Firms for Trade Fraud in China-Product Probe

Vietnam to Punish Firms for Trade Fraud in China-Product Probe(Bloomberg) -- Vietnam will punish four companies for fraudulent labels on products from China that the firms claim were made locally, as authorities expand their crackdown into Chinese manufacturers trying to bypass U.S. tariffs.The unidentified companies, which assemble bicycles, electric bikes and wooden shelves, admitted to the violations, according to a government statement. Vietnam’s customs department is also investigating possible violations by five other firms, and expanding the probe into other products such as solar energy batteries and LED lights.The agency has also ordered customs units in nine cities and provinces to look into the activities of 24 other companies. It is calling for closer examination of firms that set up operations from late 2018 and which import Chinese spare parts and accessories for export to the U.S. and European Union.Vietnam has strict rules on what constitutes being manufactured locally, while its trading partners could also take action against the country for not preventing goods from being mislabeled and allowing trade fraud. The U.S has threatened to impose tariffs on the Southeast Asian nation because of its rising trade surplus with the U.S.Hanoi is stepping up efforts to stop exporters from China from trying to route products through Vietnam in an attempt to avoid higher U.S. tariffs. Hanoi is under growing pressure from Washington as its trade surplus with the U.S. surges.Vietnam’s goods surplus with the U.S. climbed to $46.3 billion in the first 10 months of 2019 -- a 39% increase from the same period last year -- making it a target for the White House. President Donald Trump has called Vietnam a trade abuser, with the U.S. slapping tariffs of more than 400% on steel from Vietnam due to charges of illegal trans-shipment.To contact the reporters on this story: John Boudreau in Hanoi at jboudreau3@bloomberg.net;Mai Ngoc Chau in Ho Chi Minh City at cmai9@bloomberg.netTo contact the editors responsible for this story: Shamim Adam at sadam2@bloomberg.net, Colum MurphyFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.




from Yahoo Finance https://ift.tt/351Kl93

Labels:

Comments

Post a Comment

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $
Post a Comment
Read more

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be
Post a Comment
Read more